A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Inclusion Criteria Patients must have: HIV infection. Antiretroviral naiveness (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs. No more than 2 weeks of prior treatment with a protease inhibitor. No active opportunistic infection or other serious AIDS-defining condition. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Malabsorption or inadequate oral intake. Lab or clinical abnormality worse than grade 3 (other than exercise-induced CPK elevations). Unexplained, chronic diarrhea, defined as more than three loose stools per day persisting for 2 weeks or more within the month prior to study entry. Active malignancy or anticipated need for chemotherapy during the study. Anticipated need for disallowed medications during the study. Concurrent Medication: Excluded: Other protease inhibitors. Prior Medication: Excluded: More than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen. More than 2 weeks of any protease inhibitor.